Cervical Cancer Treatment Guidelines

Introduction to Treatment by FIGO Stage

The American College of Obstetricians and Gynecologists recommends treatment for cervical cancer based on FIGO stage, with early-stage disease managed primarily by surgery, locally advanced disease treated with concurrent chemoradiation using weekly cisplatin, and metastatic/recurrent disease requiring platinum-based chemotherapy with bevacizumab 1, 2

For stage IA1 without lymphovascular space invasion, conization with negative margins or simple hysterectomy is recommended based on patient age 3, 2
For stage IA1 with lymphovascular space invasion, adding pelvic lymphadenectomy to the above surgical approach is recommended 3, 2
For stage IA2, radical hysterectomy with mandatory pelvic lymphadenectomy is the standard approach, with fertility-sparing options available for young patients desiring fertility 3, 4
For stage IB1 and IIA1, primary treatment options include radical hysterectomy with pelvic lymphadenectomy, external beam radiation plus brachytherapy, and combined radio-surgery, with conservative surgery considered for tumors with excellent prognostic factors 3, 2, 4
For stage IB2 and IIA2, concurrent chemoradiation is preferred over surgery for tumors >4 cm, with a chemoradiation regimen of weekly cisplatin 40 mg/m² during external beam radiation therapy 2, 1
For stage IIB-IVA, standard treatment is concurrent chemoradiation with weekly cisplatin 40 mg/m², providing an absolute 5-year survival benefit of 8% for overall survival 1, 2, 4

For young women with stage IA1-IB1 disease, fertility preservation options include cone biopsy with negative margins or trachelectomy 2, 4
Ovarian preservation may be considered for premenopausal women with squamous cell carcinoma undergoing hysterectomy, with ovarian transposition recommended before pelvic radiation in women <45 years 2

The American College of Obstetricians and Gynecologists recommends follow-up with clinical and gynecological examination with PAP smear every 3 months for the first 2 years, every 6 months for years 3-5, and yearly after 5 years, with additional monitoring including annual cervical/vaginal cytology and imaging as indicated 3, 2